Adalenk

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

 

 

SKU: 198803 Kategorija:
Pasidalinkite savo meile

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

The peptide is designed as a derivative of the nootropic drug Selank, with the addition of an acetylated N-terminal function that enhances its adamantane-like sterically-constraining structure.

This modification acts as a powerful synergistic potentiator of the anxiolytic – nootropic compound Selank.

It circumvents Selank’s poor kraujo-smegenų barjeras (BBB) penetration, thereby increasing the central nervous system activity of Adalank significantly.

The addition of an acetyl group eliminates the positive charge of the N-terminal free amino group and decreases the net charge of the peptide.

This physicochemical adjustment optimizes the isoelectric point and surface properties of Adalank, reducing non-specific electrostatic interactions.

Dėl to, the drug molecule crosses the blood–brain barrier more easily and reaches the central nervous system.

Be to, acetilinimas protects Adalank from exopeptidase degradation and significantly increases its in vivo half-life.

This provides the advantage of prolonged therapeutic blood levels and reduces frequent dosing.

The inclusion of adamantane creates a stable “conformation core” in the Adalank peptide.

This imparts a fixed spatial orientation to the initially flexible linear peptide, promoting the stereochemical conformation necessary for biological activity even in its unbound state.

This greatly improves Adalank’s ability to cross the blood-brain barrier.

In addition, Adalank exhibits certain immunomodulatory effects.

Seka

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS numeris

/

Molekulinė formulė

C46H75N13O10

Molekulinė masė

970.19

Research Of Adalank:

1.Veikimo mechanizmas

Veiksmingumo požiūriu, Adalank’s rigid structure more closely corresponds to the allosteric modulation site of the GABA_A receptor alpha subunit, imparting stronger anksiolitinis efektai.

Be to, the adamantane moiety enables hydrophobic interactions in the NMDA receptorius channel area to moderate calcium influx and protect against excitotoxic injury.

This property has the potential for neuroprotection in models of ischemic brain injury and post-traumatic stress disorder (PTSD).

2.Anxiolytic Effects

As an optimized derivative of Selank, Adalank maintains a high-affinity interaction with the benzodiazepine site on the GABA_A receptor α-subunit.

Tačiau, the N-terminal acetylation and adamantane scaffold shift the binding mode from “flexible induced fit” to “rigid precise docking”.

This enhances GABAergic inhibitory neurotransmission, promoting chloride influx and rapid reduction of activity in hyperactive amygdala-prefrontal cortex neural circuits.

In contrast to benzodiazepines, Adalank shows high receptor subtype selectivity, enabling sustained anxiolytic effects without the sedation, muscle relaxation, or addiction potential associated with traditional drugs.

Its therapeutic index is 3 į 5 times wider, supporting long-term management of generalized anxiety disorder and situational anxiety disorders.

3.Cognitive Enhancement and Memory Improvement

Adalank effectively inhibits the activation of the NF-κB inflammatory pathway and increases BDNF mRNR expression by 50%-80% in the hipokampas.

This leads to activation of downstream Akt/CREB signaling pathways, facilitating LTP induction and maintenance.

It significantly improves memory retention in passive avoidance tests, enhances spatial learning in the Morris water maze, and counteracts scopolamine-induced cholinergic damage.

Preclinical data indicate that Adalank reduces working memory errors by 40%-60% and mitigates natural memory decline in aged animals, suggesting applicability in learning disorders, mild cognitive impairment, and age-related memory decline.

4.Neuroprotekcinis poveikis

The adamantane structure in Adalank mimics the action of memantine, acting as a non-competitive NMDA receptorius antagonist that causes voltage-dependent blockade of open channels and physiological regulation of calcium influx.

It reduces pathological Ca²⁺ influx by 60–70% without impairing physiological synaptic Ca²⁺ signaling, achieving a selective neuroprotective profile without disrupting normal function.

Taigi, preclinical studies highlight Adalank’s significant translational potential for early intervention in acute stroke, spinal cord injury, ir neurodegeneracinės ligos.

COA

HPLC

MS

(1) Mes norime, C. R.; Baltas, C. M. Raminamieji-migdomieji preparatai, veikiantys gama aminosviesto rūgšties receptorius: Dėmesys Flunitrazepamui, Gama-hidroksisviesto rūgštis, Fenibutas, ir Selankas. J Clin Pharmacol 2021, 61 Suppl 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Vargšas, A.; Kolominas, T.; Andreeva, L.; Bondarenko, E.; Myasoedovas, N.; Slominskis, P.; Šadrina, M. Peptidas Selankas sustiprina diazepamo poveikį mažinant nerimą nenuspėjamomis lėtinėmis lengvomis žiurkių streso sąlygomis. Elgesys Neurol 2017, 2017, 50910

(3) Smeigtukas, L. G.; Nadorova, A. V.; Antipova, T. A.; Kruglovas, S. V.; Kudrinas, V. S.; Durnevas, A. D. Selankas, Tuftsin peptidų analogas, Apsaugo nuo etanolio sukelto atminties sutrikimo reguliuodamas BDNF kiekį hipokampe ir prefrontalinėje žievėje

(4) Smeigtukas, L. G.; Nadorova, A. V.; Seredeninas, S. B. Selankas slopina etanolio sukeltą hiperlokomodiją ir DBA/2 pelių elgesio jautrumo pasireiškimą. Bull Exp Biol Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 Iš NLM Medline.

(5) Kaina, N. V.; Sokolovas, O.; Gabaeva, M. V.; Grivennikovas, aš. A.; Andreeva, L. A.; Miasoedovas, N. F.; Zozulija, A. A. [Semax ir selank slopina enkefaliną skaidančius fermentus iš žmogaus serumo]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/a:10113730028

(6) aš nežinau, G. G.; Telešova, E. S.; Bočkarevas, V. K.; Koschelevas, V. V.; Siunjakovas, T. S. P.3.036 Naujas anksiolitikas Selankas: II fazės klinikinių tyrimų rezultatai. Europos neuropsichofarmakologija 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Slominskis, P. A.; Šadrina, M. aš.; Kolominas, T. A.; Stavrovskaja, A. V.; Filatova, E. V.; Andreeva, L. A.; Illarioškinas, S. N.; Myasoedovas, N. F. Peptidai semax ir selank veikia žiurkių, turinčių 6-OHDA sukeltą PD panašų parkinsonizmą, elgesį. Iki Biol Sc

(8) Sollertinskaja, T. N.; Šorohovas, M. V.; Myasoedovas, N. F. Semax ir Selank smegenų apsaugas primatams, sergantiems įvairių tipų neurozėmis. Tarptautinis psichofiziologijos žurnalas 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

Seka:

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS:

N/A

M.W:

970.19 g/mol

Pradžia Ieškoti Whatsapp Paslaugos Produktas